Sarah Christensen, D.V.M., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Migraine Disorders | 18 | 2024 | 1713 | 4.460 |
Why?
|
| Calcitonin Gene-Related Peptide | 11 | 2024 | 328 | 2.830 |
Why?
|
| Pituitary Adenylate Cyclase-Activating Polypeptide | 5 | 2024 | 108 | 2.700 |
Why?
|
| KATP Channels | 3 | 2022 | 49 | 2.240 |
Why?
|
| Nitroglycerin | 7 | 2024 | 332 | 2.000 |
Why?
|
| Receptors, Vasoactive Intestinal Polypeptide, Type I | 1 | 2024 | 5 | 0.960 |
Why?
|
| Receptors, Vasoactive Intestinal Peptide, Type II | 1 | 2024 | 7 | 0.960 |
Why?
|
| Meninges | 1 | 2024 | 197 | 0.830 |
Why?
|
| Cromakalim | 4 | 2022 | 23 | 0.810 |
Why?
|
| Locomotion | 1 | 2024 | 390 | 0.790 |
Why?
|
| Disease Models, Animal | 9 | 2024 | 18362 | 0.750 |
Why?
|
| Glyburide | 1 | 2020 | 117 | 0.660 |
Why?
|
| Receptors, Calcitonin Gene-Related Peptide | 1 | 2019 | 31 | 0.660 |
Why?
|
| Vasodilator Agents | 3 | 2022 | 990 | 0.660 |
Why?
|
| Pain Threshold | 2 | 2020 | 606 | 0.640 |
Why?
|
| Sulfonylurea Compounds | 1 | 2020 | 220 | 0.610 |
Why?
|
| Pain | 4 | 2024 | 5103 | 0.590 |
Why?
|
| Mice, Knockout | 4 | 2024 | 14481 | 0.520 |
Why?
|
| Trigeminal Ganglion | 3 | 2022 | 186 | 0.520 |
Why?
|
| Drug Hypersensitivity | 1 | 2022 | 923 | 0.440 |
Why?
|
| Behavior, Animal | 2 | 2024 | 1879 | 0.430 |
Why?
|
| Light | 1 | 2016 | 1354 | 0.340 |
Why?
|
| Hyperalgesia | 3 | 2024 | 527 | 0.330 |
Why?
|
| Rodentia | 2 | 2022 | 262 | 0.320 |
Why?
|
| Mice | 13 | 2024 | 82017 | 0.300 |
Why?
|
| Drug Delivery Systems | 1 | 2019 | 2237 | 0.290 |
Why?
|
| Animals | 17 | 2024 | 169337 | 0.260 |
Why?
|
| Motor Activity | 1 | 2016 | 2720 | 0.260 |
Why?
|
| Adenosine Triphosphate | 2 | 2022 | 2002 | 0.250 |
Why?
|
| Sumatriptan | 2 | 2022 | 66 | 0.250 |
Why?
|
| Quinazolines | 3 | 2020 | 1373 | 0.240 |
Why?
|
| Peroxynitrous Acid | 1 | 2024 | 40 | 0.240 |
Why?
|
| Mice, Inbred C57BL | 5 | 2024 | 22355 | 0.240 |
Why?
|
| Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I | 1 | 2024 | 53 | 0.230 |
Why?
|
| Rats | 5 | 2022 | 23835 | 0.220 |
Why?
|
| Cluster Headache | 1 | 2024 | 54 | 0.220 |
Why?
|
| Transient Receptor Potential Channels | 1 | 2023 | 130 | 0.210 |
Why?
|
| Hindlimb | 1 | 2024 | 516 | 0.200 |
Why?
|
| Fund Raising | 1 | 2021 | 49 | 0.190 |
Why?
|
| Calcitonin | 1 | 2022 | 329 | 0.180 |
Why?
|
| Piperazines | 3 | 2020 | 2552 | 0.180 |
Why?
|
| Vasodilation | 1 | 2024 | 968 | 0.170 |
Why?
|
| Injections, Intraventricular | 1 | 2020 | 227 | 0.170 |
Why?
|
| Carotid Arteries | 1 | 2024 | 943 | 0.170 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2020 | 8199 | 0.170 |
Why?
|
| Algorithms | 1 | 2020 | 14154 | 0.160 |
Why?
|
| Physical Stimulation | 1 | 2020 | 517 | 0.150 |
Why?
|
| Dura Mater | 1 | 2020 | 297 | 0.150 |
Why?
|
| Headache | 2 | 2024 | 1262 | 0.150 |
Why?
|
| Muscle, Smooth | 1 | 2021 | 930 | 0.140 |
Why?
|
| Dipeptides | 1 | 2019 | 386 | 0.140 |
Why?
|
| Oxidoreductases | 1 | 2019 | 412 | 0.140 |
Why?
|
| Estrous Cycle | 1 | 2016 | 65 | 0.130 |
Why?
|
| Photophobia | 1 | 2016 | 77 | 0.130 |
Why?
|
| Trigeminal Caudal Nucleus | 1 | 2014 | 18 | 0.120 |
Why?
|
| Solitary Nucleus | 1 | 2014 | 54 | 0.110 |
Why?
|
| Infusions, Intravenous | 2 | 2016 | 2226 | 0.110 |
Why?
|
| Environmental Pollutants | 1 | 2023 | 1290 | 0.110 |
Why?
|
| Medulla Oblongata | 1 | 2014 | 248 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2014 | 583 | 0.090 |
Why?
|
| Running | 1 | 2016 | 490 | 0.090 |
Why?
|
| Pain Measurement | 1 | 2020 | 3581 | 0.080 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2015 | 2596 | 0.080 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2015 | 1360 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2021 | 12805 | 0.070 |
Why?
|
| Point-of-Care Systems | 1 | 2015 | 1238 | 0.060 |
Why?
|
| Inflammation | 1 | 2024 | 10863 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2024 | 175 | 0.060 |
Why?
|
| Humans | 9 | 2024 | 768393 | 0.050 |
Why?
|
| Xenobiotics | 1 | 2023 | 71 | 0.050 |
Why?
|
| Physicians | 1 | 2021 | 4614 | 0.050 |
Why?
|
| Male | 6 | 2024 | 364902 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 9261 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2024 | 515 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 20224 | 0.050 |
Why?
|
| Nitric Oxide Synthase | 1 | 2024 | 911 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2024 | 706 | 0.050 |
Why?
|
| Tryptamines | 1 | 2020 | 93 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2022 | 23631 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2015 | 4571 | 0.040 |
Why?
|
| Brain | 1 | 2024 | 27454 | 0.040 |
Why?
|
| Faculty, Medical | 1 | 2021 | 1218 | 0.030 |
Why?
|
| Zidovudine | 1 | 2015 | 625 | 0.030 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 1088 | 0.020 |
Why?
|
| Female | 4 | 2021 | 397089 | 0.020 |
Why?
|
| Calcium | 1 | 2023 | 5794 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2021 | 2349 | 0.020 |
Why?
|
| South Africa | 1 | 2015 | 1871 | 0.020 |
Why?
|
| HIV Infections | 1 | 2015 | 17575 | 0.020 |
Why?
|
| Research Design | 1 | 2024 | 6210 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2015 | 1249 | 0.020 |
Why?
|
| Sex Factors | 1 | 2021 | 10654 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2024 | 22296 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 5538 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2015 | 3267 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 11918 | 0.010 |
Why?
|
| United States | 1 | 2021 | 73150 | 0.010 |
Why?
|
| Pregnancy | 1 | 2015 | 30200 | 0.010 |
Why?
|
| Infant | 1 | 2015 | 36510 | 0.010 |
Why?
|
| Young Adult | 1 | 2015 | 60049 | 0.000 |
Why?
|
| Child | 1 | 2015 | 80891 | 0.000 |
Why?
|
| Adult | 1 | 2015 | 223640 | 0.000 |
Why?
|